# 503A 503B peptide sourcing: what pharmacies need from an API supplier

> Under section 503A, pharmacies compound for identified patients using bulk substances that meet statutory conditions. Section 503B outsourcing facilities use substances on FDA's 503B list. A draft HHS enforcement discretion policy published October 30, 2026 covers six peptides for 503A only. It is not approval.

Source: https://internationalwholesalepeptides.com/guides/503a-503b-peptide-sourcing/
Updated: 2026-11-18

This guide to 503A 503B peptide sourcing explains the two compounding pathways in US law, how bulk drug substance lists work, what the HHS draft policy published on October 30, 2026 says about six peptides, and what a pharmacy must ask an API supplier for. It is general information as of November 18, 2026. It is not legal advice, and the position is unsettled. Pharmacies must confirm requirements with FDA, their state board of pharmacy and counsel.

## How 503A and 503B differ

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act set conditions under which compounded drugs are exempt from certain requirements. FDA summarizes both on its [human drug compounding laws](https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws) page.

| Feature | Section 503A | Section 503B |
|---|---|---|
| Who | State-licensed pharmacies, federal facilities, licensed physicians | Outsourcing facilities registered with FDA |
| Prescription | Compounding for an identified individual patient on a valid prescription | Patient-specific prescriptions not required |
| cGMP | Exempt from cGMP if the section's conditions are met | cGMP applies |
| New drug approval | Exempt if conditions are met | Exempt if conditions are met |
| Primary oversight | State boards of pharmacy, with FDA authority over conditions such as insanitary conditions | FDA, with risk-based inspections |
| Bulk drug substances | Three statutory routes; see below | Substances on the 503B bulks list, or drugs on FDA's shortage list |
| Reporting | State requirements | Product reporting and adverse event reporting to FDA |

FDA publishes a list of [registered outsourcing facilities](https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities) and general [information for outsourcing facilities](https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities).

## How the bulk drug substance lists work

### Under section 503A

FDA's page on [bulk drug substances used in compounding under section 503A](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) sets out three routes. A bulk drug substance may be used if it:

1. complies with an applicable United States Pharmacopeia or National Formulary monograph, if one exists, and the USP chapter on pharmacy compounding; or
2. if no monograph exists, is a component of an FDA-approved drug product; or
3. if neither applies, appears on the list FDA establishes by regulation, known as the 503A bulks list, at 21 CFR 216.23 in [21 CFR Part 216](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216).

In every case the substance must be manufactured by an establishment registered with FDA under section 510 and must be accompanied by a valid certificate of analysis.

While the list is developed through rulemaking, FDA sorted nominated substances into interim categories.

| Category | Meaning |
|---|---|
| Category 1 | Under evaluation; FDA does not intend to act against compounding with these substances if the guidance conditions are met |
| Category 2 | FDA has identified [significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); not covered by the interim policy |
| Category 3 | Nominated with insufficient information; not covered by the interim policy |

FDA states that it does not intend to categorize substances nominated on or after January 7, 2025. Several peptide substances were placed in Category 2 in 2023. During 2026, FDA announced changes to the categorization of a group of peptide substances, and its [Pharmacy Compounding Advisory Committee](https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee) considered several of them. Committee votes are advisory. Removal from a category does not place a substance on the 503A bulks list.

### Under section 503B

An outsourcing facility may compound from a bulk drug substance only if the substance appears on FDA's [503B bulks list](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act), for which FDA must find a clinical need, or if the compounded drug appears on FDA's drug shortage list. The same registration and certificate conditions apply to the substance. The 503A and 503B lists are separate. Eligibility under one does not carry over to the other.

## What the October 30, 2026 HHS draft policy says

On October 30, 2026, the Department of Health and Human Services published a notice of availability in the Federal Register titled [Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances](https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances). The official text is also on [govinfo](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm).

| Item | Detail |
|---|---|
| Citation | 91 FR 68526; FR Doc. 2026-22192 |
| Issuer | HHS, Office of the Secretary |
| Docket | [HHS-OASH-2026-0496](https://www.regulations.gov/docket/HHS-OASH-2026-0496) |
| Document type | Notice of availability of a draft policy |
| Comment period | Two weeks from publication |
| Substances named | BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500 |
| Who it addresses | State-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A |
| 503B outsourcing facilities | Not covered |
| Duration | Described as applying until each substance is addressed in a final rule on the 503A bulks list |

The notice says HHS does not intend to take enforcement action against compounding under section 503A with the listed substances when the conditions in the policy are met.

### What the draft is not

- It is a draft. The notice states that it is not binding on HHS or the public and creates no rights.
- It is not FDA approval of any peptide or of any compounded product.
- It does not add the six substances to the 503A bulks list.
- It does not cover section 503B outsourcing facilities.
- It does not change state pharmacy law, which may be stricter.
- It does not cover research-labeled products sold outside the pharmacy pathway.

As of November 18, 2026, we are not aware of a final version. Check the Federal Register and the docket for the current status before relying on it, and take counsel's advice on whether and how the draft can be relied on at all.

### Conditions that concern the API supplier

The draft sets several conditions. Those that bear on sourcing, as described in the draft and its appendices, include the following. Read the original text for the exact wording.

| Condition area | What the draft describes |
|---|---|
| Substance identity | The substance matches the identity set out in the appendix: sequence, structure, molecular formula and mass, in the stated form |
| Registered source | The bulk drug substance comes from a facility registered under section 510 |
| Original manufacturer | The original manufacturer, not only a later repackager or distributor, is registered, follows cGMP, and its physical location appears on the certificate of analysis |
| Certificate of analysis | A valid certificate with results consistent with the criteria in the appendix |
| Intermediaries | A registered repackager, relabeler or reseller must have validated the manufacturer and its certificate, and documented that validation |
| Single active ingredient | The compounded product contains one listed active ingredient |
| Reporting and labeling | The compounder reports adverse events and quality problems, including through [MedWatch](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program), and uses the required label statement |
| Other law | All other applicable requirements still apply, including the prescription requirement and the prohibition on insanitary conditions |

## 503A 503B peptide sourcing: what to ask an API supplier for

Whatever the final policy says, the statutory baseline is a registered manufacturer and a valid certificate of analysis. A sourcing file for a peptide API should contain the following.

| Request | Why |
|---|---|
| Original manufacturer's legal name and site address | The statute and the draft both turn on the manufacturer, not the reseller |
| FDA establishment registration and FEI number | Confirms registration under section 510; verify in FDA's [registration database](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-establishments-current-registration-site-decrs) |
| Lot-specific certificate of analysis | Identity, purity, assay or content, water, counter-ion, residual solvents, endotoxin and bioburden where relevant |
| Grade statement | That the material is intended for human drug compounding, not research grade |
| cGMP evidence | Signed statement plus audit report or inspection history |
| Chain of custody | Every party between manufacturer and pharmacy, with dates and lot numbers |
| Repackager validation record | Where an intermediary handled the material |
| Drug master file reference | Where one exists |
| Change notification commitment | Written, with a notice period |
| Storage and shipping record | Temperature data for the delivery |

Registration is necessary but does not prove quality. FDA states that registration does not denote approval. The full review is set out in the [peptide API supplier checklist](/guides/peptide-api-supplier-checklist/), and the difference between grades is explained in [research grade vs pharmaceutical grade](/guides/research-grade-vs-pharmaceutical-grade/). Testing methods are covered in [endotoxin and sterility testing](/guides/endotoxin-and-sterility-testing/).

## How International Wholesale Peptides supplies pharmacies

We supply [bulk API powder](/formats/bulk-api-powder/) to licensed pharmacies and manufacturers after business verification. Each lot ships with a certificate of analysis that names the testing laboratory, and origin is stated per lot. We do not sell to individuals, and clinics are supplied only through a licensed pharmacy. Pharmacies can read the page for [compounding pharmacies](/for/compounding-pharmacies/) and review individual compound sheets such as [BPC-157](/compounds/bpc-157/) before applying.

## Frequently asked questions

### What is the difference between 503A and 503B?

Section 503A covers compounding by state-licensed pharmacies and physicians for identified individual patients on valid prescriptions. Section 503B covers outsourcing facilities that register with FDA, follow cGMP and may supply without patient-specific prescriptions. Each section has its own conditions for bulk drug substances.

### Which peptides does the October 2026 HHS draft policy cover?

The draft names six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. An appendix specifies the identity and form of each substance in scope. Buyers should read the appendix, because a substance outside that description is not covered.

### Is the HHS peptide policy an FDA approval?

No. The Federal Register notice announces a draft enforcement discretion policy. It states that the draft is not binding and creates no rights. It does not approve any peptide or compounded product and does not add the substances to the 503A bulks list.

### Does the draft policy apply to 503B outsourcing facilities?

No. The draft describes enforcement discretion for state-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A. It does not extend to outsourcing facilities under section 503B, which remain subject to the 503B bulk drug substance conditions.

### What must a pharmacy ask a peptide API supplier for?

At minimum: the original manufacturer's name, address and FDA establishment registration, a lot-specific certificate of analysis, evidence of cGMP manufacture, the grade statement, endotoxin and bioburden results where relevant, and documented traceability if the material passed through a repackager or distributor.

### Can a pharmacy use research-grade peptides for compounding?

No. Research-grade material is for laboratory research by verified institutions and is not for human or veterinary use. Compounding requires bulk drug substances that meet the statutory conditions, including manufacture by an establishment registered under section 510 and a valid certificate of analysis.
